For Pharmacists

Indication

Zolpimist (zolpidem tartrate) Oral Spray CIV is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate has been shown to decrease sleep latency for up to 35 days in controlled clinical studies.1

  • Zolpimist Oral Spray contains the market leading prescribed sleep agent, zolpidem tartrate
  • Zolpimist Oral Spray is delivered as an oral spray delivered into the mouth
  • Each metered actuation of Zolpimist Oral Spray delivers 5 mg of zolpidem tartrate in 100 uL

Zolpimist Oral Spray is non-AB rated and should not be substituted.2

  • Zolpimist Oral Spray has no FDA-approved equivalent
  • Other brands of zolpidem (i.e. Ambien®, Ambien CR®, and A-rated zolpidem products) are not FDA Orange Book-approved therapeutic equivalents to Zolpimist Oral Spray

Order Zolpimist Oral Spray Today

SizeNDC
4.5 mL; 30 metered actuations58407-0510-30
7.7 mL; 60 metered actuations58407-0510-60
WholesalerItem Number
30 Dose
Item Number
60 Dose
Cardinal52287965228770
AmeriSource1016326910163268
McKesson39131423913159

Reference

  1. ZOLPIMIST [package insert]. Englewood, CO: Aytu Bio Science Inc.; 2019.
  2. Orange Book: Approved Products with Therapeutic Equivalents Evaluations.

Dispense Zolpimist in the child-resistant container in which it is packaged

  • Confirm drug & expiry date
  • Snap vial in place in child-resistant container
  • Place label on child-resistant cap or base
  • Dispense with Medication Guide*and Patient’s Instructions for Use*

*Provided as part of Package Insert

Unit of Use

A prescription represents one single unit

Each single spray provides 5 mg of zolpidem tartrate

Unique Oral Mist Delivery System

Zolpimist spray is applied directly to the back of the throat and is absorbed by the oral mucosa

Fast-acting oral mist spray gives the patient control, dosing right before bed without the need for water, in a unique patented formulation

Reimbursed by insurers for most patients

WARNING: COMPLEX SLEEP BEHAVIORS

Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of ZOLPIMIST. Some of these events may result in serious injuries, including death. Discontinue ZOLPIMIST immediately if a patient experiences a complex sleep behavior.

INDICATIONS AND USAGE

ZOLPIMIST (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate has been shown to decrease sleep latency for up to 35 days in controlled clinical studies.

The clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ZOLPIMIST is contraindicated in patients:

  • Who have experienced complex sleep behaviors after taking ZOLPIMIST.
  • With known hypersensitivity to zolpidem tartrate.

WARNINGS AND PRECAUTIONS

  • Complex Sleep Behaviors: Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following the first or any subsequent use of zolpidem. Patients can be seriously injured or injure others during complex sleep behaviors. Such injuries may result in a fatal outcome. Other complex sleep behaviors (e.g., preparing and eating food, making phone calls, or having sex) have also been reported. Patients usually do not remember these events. Post-marketing reports have shown that complex sleep behaviors may occur with zolpidem alone at recommended dosages, with or without the concomitant use of alcohol or other central nervous system (CNS) depressants. Discontinue ZOLPIMIST immediately if a patient experiences a complex sleep behavior.
  • CNS Depressant Effects and Next-Day Impairment: Zolpidem tartrate, like other sedative-hypnotic drugs, has CNS-depressant effects. Due to the rapid onset of action, ZOLPIMIST should only be administered immediately prior to going to bed. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following administration of ZOLPIMIST.
  • Need to Evaluate for Co-Morbid Diagnoses: Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.
  • Severe Anaphylactic and Anaphylactoid Reactions: Rare cases of angioedema involving the tongue, glottis, or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including zolpidem.
  • Abnormal Thinking and Behavioral Changes: A variety of abnormal thinking and behavioral changes have been reported to occur in association with the use of sedative-hypnotics.
  • Withdrawal Effects: Following the rapid dose decrease or abrupt discontinuation of sedative-hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs.
  • Special Populations:

Use in the elderly and/or debilitated patients: Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative-hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended ZOLPIMIST dosage is 5 mg in such patients to decrease the possibility of side effects. These patients should be closely monitored.

Use in patients with concomitant illness: Clinical experience with zolpidem tartrate in patients with concomitant systemic illness is limited. Caution is advisable in using ZOLPIMIST in patients with diseases or conditions that could affect metabolism or hemodynamic responses.

ADVERSE EVENT REPORTING
To report suspected adverse events or product complaints, please contact Aytu BioScience at 855-AYTU-BIO; FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Open ISI

WARNING: COMPLEX SLEEP BEHAVIORS

Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of ZOLPIMIST. Some of these events may result in serious injuries, including death. Discontinue ZOLPIMIST immediately if a patient experiences a complex sleep behavior.

INDICATIONS AND USAGE

ZOLPIMIST (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate has been shown to decrease sleep latency for up to 35 days in controlled clinical studies.

The clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ZOLPIMIST is contraindicated in patients:

  • Who have experienced complex sleep behaviors after taking ZOLPIMIST.
  • With known hypersensitivity to zolpidem tartrate.

WARNINGS AND PRECAUTIONS

  • Complex Sleep Behaviors: Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following the first or any subsequent use of zolpidem. Patients can be seriously injured or injure others during complex sleep behaviors. Such injuries may result in a fatal outcome. Other complex sleep behaviors (e.g., preparing and eating food, making phone calls, or having sex) have also been reported. Patients usually do not remember these events. Post-marketing reports have shown that complex sleep behaviors may occur with zolpidem alone at recommended dosages, with or without the concomitant use of alcohol or other central nervous system (CNS) depressants. Discontinue ZOLPIMIST immediately if a patient experiences a complex sleep behavior.
  • CNS Depressant Effects and Next-Day Impairment: Zolpidem tartrate, like other sedative-hypnotic drugs, has CNS-depressant effects. Due to the rapid onset of action, ZOLPIMIST should only be administered immediately prior to going to bed. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following administration of ZOLPIMIST.
  • Need to Evaluate for Co-Morbid Diagnoses: Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.
  • Severe Anaphylactic and Anaphylactoid Reactions: Rare cases of angioedema involving the tongue, glottis, or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including zolpidem.
  • Abnormal Thinking and Behavioral Changes: A variety of abnormal thinking and behavioral changes have been reported to occur in association with the use of sedative-hypnotics.
  • Withdrawal Effects: Following the rapid dose decrease or abrupt discontinuation of sedative-hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs.
  • Special Populations:

Use in the elderly and/or debilitated patients: Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative-hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended ZOLPIMIST dosage is 5 mg in such patients to decrease the possibility of side effects. These patients should be closely monitored.

Use in patients with concomitant illness: Clinical experience with zolpidem tartrate in patients with concomitant systemic illness is limited. Caution is advisable in using ZOLPIMIST in patients with diseases or conditions that could affect metabolism or hemodynamic responses.

ADVERSE EVENT REPORTING
To report suspected adverse events or product complaints, please contact Aytu BioScience at 855-AYTU-BIO; FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.